Investigation of the effect of thymoquinone on kidney damage in isoproterenol-induced myocardial infarction in rats and cardiorenal interactions

Abstract

This study aimed to determine whether thymoquinone has any protective effects on renal tissue after an isoproterenol-induced myocardial infarction (MI). Experimental groups were formed as 4 groups (n=8). Control group (C). Thymoquinone group (THQ), 20 mg/kg single dose intragastric (i.g.) daily for seven days. Isoproterenol group (ISO) was administered 100 mg/kg intraperitoneally in two doses on days 7 and 8 of the experiment. Thymoquinone+Isoproterenol group (THQ+ISO), THQ 20 mg/kg i.g. was administered once a day for seven days. In addition, two doses of ISO 100 mg/kg i.p. were administered on the seventh and eighth days. Kidney tissues were evaluated histopathologically. Kidney tissues were evaluated histopathologically. Tumour necrosis factor alpha(TNF-α) and alpha Smooth Muscle Actin(α-SMA) immunoreactivity density changes were determined by immunohistochemistry. Glutathione(GST), Glutathione S-transferases(GSTs) and Interleukin-6(IL-6) levels were evaluated by ELISA method. Isoproterenol injection caused severe histopathological changes on kidney tissue. Also TNF-α and α-SMA levels were found to be higher in groups where ISO was administered. THQ could be effective on kidney tissue to partially correct these histopathological damages, by decreasing fibrosis and inflammation. This study shows that treatment with THQ is effective in preventing kidney damage caused by ISO-induced MI. We think that THQ as a supplementary food will be effective to prevent kidney damage.

Keywords

• Isoproterenol
• Thymoquinone
• Inflamation
• Fibrosis
• Kidney

Supporting Institution

---

Project Number

21/129

Ethical Statement

Ethics committee approval was obtained from Erciyes University Animal Experiments Local Ethics Committee for the tissues used in this study (approval dated 02.06.2021 and numbered 21/129). The study was carried out in accordance with the principles of "Guide for the Care and Use of Laboratory Animals".

Thanks

---

References

1. 1. Ou L, Li W, Liu Y, et al. Animal Models of Cardiac Disease and Stem Cell Therapy. Open Cardiovasc Med J. 2010;4:231-9.
2. 2. Zaragoza C, Gomez-Guerrero C, Martin- Ventura JL, et al. Animal models of cardiovascular diseases. Biomed Res Int. 2011;2011: 497841.
3. 3. Alam MN, Hossain MM, Rahman MM, et al. Astaxanthin prevented oxidative stress in heart and kidneys of isoproterenoladministered aged rats. J Diet Suppl. 2018;15:42-54.
4. 4. Vasanthi HR. Shri Shri Mal N, Das KD. Phytochemicals from Plants to Combat Cardiovascular Disease. Curr Med Chem. 2012;19:2242-51.
5. 5. Haidarali S, Patil CR, Ojha S, et al. Targeting apoptotic pathways in myocardial infarction: attenuated by phytochemicals. Cardiovasc Hematol Agents Med Chem. 2014;12(2):72-85.
6. 6. Morooka S, Hayashi T, Takayanagi Kan, et al. Effects of secondary organ failure on compensation of acute heart failure in patients with myocardial infarct and dilated cardiomyopathy: Compensatory mechanisms and their limitations in heart failure. Circ J. 1992;56:518-23.
7. 7. Ghartavol MM, Gholizadeh-Ghaleh Aziz S, Babaei G, et al. The protective impact of betaine on the tissue structure and renal function in isoproterenol-induced myocardial infarction in rat. Mol. Genet. Genomic Med. 2019;7:e00579.
8. 8. Kumar U, Wettersten N, Garimella PS. Cardiorenal syndrome: pathophysiology. Cardiol Clin. 2019;37(3):251-65.

9. 9. Ali BH, Blunden G. Pharmacological and toxicological properties of Nigella sativa. Phytother Res. 2003;17:299-305.
10. 10. Darakhshan S, Pour AB, Colagar AH, et al. Thymoquinone and its therapeutic potentials. Pharmacol Res. 2015;95:138-58.
11. 11. Ahmad SS, Najmi AK, Kaundal M, et al. Gastroprotective effect of Thymoquinone on water immersion restraint stress induced ulceration in rats. Drug Res. 2017;67:366-72.
12. 12. Daba MH, Abdel-Rahman MS. Hepatoprotective activity of thymoquinone in isolated rat hepatocytes. Toxicol Lett. 1998;95:23-9.
13. 13. Landucci E, Mazzantini C, Buonvicino D, et al. Neuroprotective effects of Thymoquinone by the modulation of ER stress and apoptotic pathway in in vitro model of excitotoxicity. Molecules. 2021;26:1592.
14. 14. Fouda AMM, Daba MHY, Dahab GM, et al. Thymoquinone ameliorates renal oxidative damage and proliferative response induced by mercuric chloride in rats. Basic Clin Pharmacol Toxicol. 2008;103:109-18.
15. 15. Harzallah HJ, Neffati A, Skandrani I, et al. Antioxidant and antigenotoxic activities of Globularia alypum leaves extracts. J Med Plants Res. 2010;4:2048-53.
16. 16. Bray TM, Taylor CG. Tissue glutathione, nutrition, and oxidative stress. Can J Physiol Pharmacol. 1993;71:746-51.
17. 17. Oakley A. Glutathione transferases: a structural perspective. Drug Metab Rev. 2011;43:138-51.
18. 18. Elbarbry F, Ragheb A, Marfleet T, et al. Modulation of hepatic drug metabolizing enzymes by dietary doses of thymoquinone in female New Zealand White rabbits. Phytother Res. 2012;26:1726- 30.
19. 19. Amin HM, El-Feki MA, Refaat IH, et al. Protective and anti-oxidant effects of thymoquinone against asthma sensitized by aspergillus fumigatus in albino rats. Curr Sci Int. 2015;4:538-47. 20. Chawla LS, Seneff MG, Nelson DR, et al. Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis. Clin J Am Soc Nephrol. 2007;2(1):22-30.
20. 21. Guo J, Yang Z, Jia Q, et al. Pirfenidone inhibits epithelial-mesenchymal transition and pulmonary fibrosis in the rat silicosis model. Toxicol Lett. 2019;300:59-66.
21. 22. Agarwal S, Srivastava R, Mishra N. An overview of therapeutic potential of thymoquinone. Int J Pharm Sci Res. 2019;10:3532-9.
22. 23. Ozmen R, Değer N, Karabulut D. Evaluation of the cytoprotective effects of thymoquinone on isoproterenol-induced rat aorta. Cukurova Med J. 2022;47:79-86.
23. 24. Yildirim AB, Ozdamar S, Kaymak E. The effects of maternal hypothyroidism on the immunoreactivity of cytochrome p450 aromatase in the postnatal rat testicles. Acta Endocrinologica (Bucharest. 2017;13(1):7.
24. 25. Ohno K, Kuno A, Murase H, et al. Diabetes increases the susceptibility to acute kidney injury after myocardial infarction through augmented activation of renal Toll-like receptors in rats. Am J Physiol Heart Circ Physiol. 2017;313:H1130-42.
25. 26. Khattab MM, Nagi MN. Thymoquinone supplementation attenuates hypertension and renal damage in nitric oxide deficient hypertensive rats. Phytother Res. 2007;21:410-4.
26. 27. Umar S, Zargan J, Umar K, et al. Modulation of the oxidative stress and inflammatory cytokine response by thymoquinone in the collagen induced arthritis in Wistar rats. Chem Biol Interact. 2012;197:40-6.
27. 28. Woo CC, Kumar AP, Sethi G, et al. Thymoquinone: potential cure for inflammatory disorders and cancer. Biochem Pharmacol. 2012;83:443-51.
28. 29. Ojha S, Azimullah S, Mohanraj R, et al. Thymoquinone protects against myocardial ischemic injury by mitigating oxidative stress and inflammation. Evid Based Complementary Altern Med. 2015;2015:143629.
29. 30. Khalifa AA, Rashad RM, El-Hadidy WF. Thymoquinone protects against cardiac mitochondrial DNA loss, oxidative stress, inflammation and apoptosis in isoproterenol-induced myocardial infarction in rats. Heliyon. 2021;7(7).
30. 31. Rathore N, Kale M, John S, et al. Lipid peroxidation and antioxidant enzymes in isoproterenol induced oxidative stress in rat erythrocytes. Indian J Physiol Pharmacol. 2000;44:161-6.
31. 32. Closa D, Folch-Puy E. Oxygen free radicals and the systemic inflammatory response. IUBMB Life. 2004;56:185-91.
32. 33. Nicoletti A, Heudes D, Mandet C, et al. Inflammatory cells and myocardial fibrosis: spatial and temporal distribution in renovascular hypertensive rats. Cardiovasc Res. 1996;32:1096- 107.
33. 34. Sagor MAT, Tabassum N, Potol MA, et al. Xanthine oxidase inhibitor, allopurinol, prevented oxidative stress, fibrosis, and myocardial damage in isoproterenol induced aged rats. Oxid Med Cell Longev. 2015;2015.
34. 35. Rodríguez-Iturbe B, Johnson RR, Herrera- Acosta J. Tubulointerstitial damage and progression of renal failure. Kidney Int. 2005;68:S82-6.
35. 36. Rockey DC, Bell PD, Hill JA. Fibrosis- a common pathway to organ injury and failure. N Engl J Med. 2015;372:1138-49.
36. 37. Liu Q, Zhang Q, Wang K, et al. Renal denervation findings on cardiac and renal fibrosis in rats with isoproterenol induced cardiomyopathy. Sci Rep. 2015;5:18582.
37. 38. Zheng G, Cai J, Chen X, et al. Relaxin ameliorates renal fibrosis and expression of endothelial cell transition markers in rats of isoproterenol-induced heart failure. Biol Pharm Bull. 2017;40:960-6.
38. 39. Ramseyer VD, Garvin JL. Tumor necrosis factor-α: regulation of renal function and blood pressure. Am J Physiol Renal Physiol. 2013;304:F1231-42.
39. 40. Kumar P, Sulakhiya K, Barua CC, et al. TNF-α, IL-6 and IL-10 expressions, responsible for disparity in action of curcumin against cisplatin- induced nephrotoxicity in rats. Mol Cell Biochem. 2017;431:113-22.
40. 41. Zhang B, Li XL, Zhao CR, et al. Interleukin- 6 as a predictor of the risk of cardiovascular disease: a meta-analysis of prospective epidemiological studies. Immunol Invest. 2018;47:689-99.
41. 42. Hannan MA, Zahan MS, Sarker PP, et al. Protective effects of black cumin (Nigella sativa) and its bioactive constituent, thymoquinone against kidney injury: An aspect on pharmacological insights. Int J Mol Sci. 2021;22:9078.
42. 43. Samra RM, Zaki AA, Shaker M, et al. Occurrence and Bioactivity Diversity of Thymoquinone: An Overview. Octahedron Drug Res. 2022;1:65-84.